A variant in the adenomatous polyposis coli gene, APC E1317Q, has been inconsistently associated with risk of colorectal cancer. We used data collected as a part of the Molecular Epidemiology of Colorectal Cancer study, a population-based study of colorectal cancer in northern Israel (1,834 matched cases and controls), to evaluate the relationship between this variant and risk of sporadic colorectal cancer. There was no association between E1317Q and colorectal cancer [odds ratio (OR), 1.15; 95% CI, 0.65-2.02]. When the control sample was restricted to polyp-free controls, the OR was 0.87 (95% CI, 0.36-2.14), indicating that this result is unlikely to be due to nondifferential misclassification due to undiagnosed polyps. A meta-analysis including these data and prior published reports found a nonsignificant summary OR nearly identical to the association reported here in the Molecular Epidemiology of Colorectal Cancer case-control study. Although there are previously published reports addressing this question, due to the low frequency of the variant, many of these studies lack the power to estimate the risk in a meaningful way. Given the substantial size of our study and the consistency of our findings with the results of our meta-analyses, we conclude that it is unlikely that APC E1317Q is associated with a clinically meaningful risk of colorectal cancer.
Introduction
Germ line truncating mutations in the APC (adenomatous polyposis coli) gene (5q21-22) cause familial adenomatous polyposis, which is characterized by thousands of polyps during adolescence and early-onset colorectal cancer. Several putative low-penetrance susceptibility alleles of APC, such as APC E1317Q, have been investigated in affected individuals with a family history of disease and in populations at risk. The APC E1317Q missense variant was first described by White et al. (1) in two of four siblings in an Ashkenazi Jewish colorectal cancer family. APC E1317Q has been reported to confer an increased risk of colorectal adenomas and cancer in some (2) (3) (4) (5) but not all (6) (7) (8) (9) (10) case-control studies. To clarify the divergent findings from previous reports, the present study investigates the relationship between E1317Q and colorectal cancer in a large population-based case-control study of colorectal cancer in northern Israel.
Study Design and Methods
Participants were recruited as a part of the Molecular Epidemiology of Colorectal Cancer study. Residents of the Northern and Haifa districts of Israel who were diagnosed with histopathologically confirmed, incident colorectal cancer between March 31, 1998 and April 1, 2004 were eligible as cases. Population-based controls were identified from the Clalit Health Services database and were individually matched to cases by year of birth, gender, primary clinic location, and ethnicity (Jewish versus non-Jewish). A detailed description of the ascertainment, eligibility, and participation rates has been previously published (11) .
Genotyping for the known susceptibility variant APC I1307K was done as described elsewhere (12) using an allelespecific oligohybridization assay. Genotyping for APC E1317Q used an allele-specific oligohybridization and oligonucleotides corresponding to the wild-type or mutant sequence at codon 1317, 5 ¶-AGGTCAGCTGAAGATCCT-3 ¶ and 5 ¶-AGGTCAGCT-CAAGATCCT-3 ¶, respectively. The assay was validated using 10 subjects (3 carriers and 7 noncarriers) by sequencing in forward and reverse, with 100% correspondence. Eighty subjects were repeated during genotyping, also with 100% correspondence.
Conditional and unconditional logistic regression were used for analyzing the presence or absence of APC E1317Q (SAS Institute, Cary, NC, 1999). Potential confounding factors (Ashkenazi versus non-Ashkenazi ethnicity, family history of colorectal cancer in a first-degree relative, weekly use of nonsteroidal anti-inflammatory drugs/aspirin for at least 1 year, and APC I1307K) were included in a multivariable model. Data regarding colonoscopy, sigmoidoscopy, or bowel surgery on the control subjects were obtained through interview. Fixed effect (Mantel-Haenszel) summary odds ratios (OR) and Woolf's test of heterogeneity were calculated using the rmeta library in R (http://www.r-project.org).
Results
The data were comprised of 1,834 matched pairs from 1,970 cases and 1,994 controls with available DNA for genotyping ( Table 1 ). The proportion of subjects of Ashkenazi Jewish ethnicity was higher in cases than controls, which is consistent (N = 1,970) , the OR for E1317Q was 0.87 (95% CI, 0.39-1.91). No controls who reported polyps carried the E1317Q mutation (0 of 87).
We completed a meta-analysis of seven previous studies, in addition to our data, to summarize the association among E1317Q, colorectal cancer, and adenomas (Table 2; Fig. 1 ). Two of the three studies reporting a positive association use the same group of controls reported by White et al. group (3, 4) , and the other study (5) uses some of the cases in the Lamlum and Frayling studies. The Lamlum et al. study also uses controls and five cases from the Frayling et al. study. A case was defined as colorectal cancer or adenoma, and controls were included without regard to polyp status. The results were essentially the same when analyzed with and without inclusion of adenoma cases. The summary OR for these eight studies was 1.35 (95% CI, 0.92-1.97; Woolf's test of heterogeneity, P = 0.14). However, when excluding the one positive association of 
